Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.

Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, Alhan C, de Loosdrecht AA, Schwäble J, Pfluger T, Tchinda J, Schmugge M, Jauch A, Naundorf S, Kühlcke K, Notheis G, Güngor T, Kalle CV, Schmidt M, Grez M, Seger R, Reichenbach J.

Curr Gene Ther. 2015;15(4):416-27.

PMID:
25981636
2.

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.

Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.

3.

Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.

Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kühlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Maródi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C.

Sci Transl Med. 2014 Mar 12;6(227):227ra33. doi: 10.1126/scitranslmed.3007280.

4.

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.

Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K, Westwood N, Thistlethwaite F, Hawkins RE, Gilham DE.

Cancer Immunol Immunother. 2014 Feb;63(2):133-45. doi: 10.1007/s00262-013-1492-9. Epub 2013 Nov 5.

PMID:
24190544
5.

From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

Stein S, Scholz S, Schwäble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Müller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson RG Jr, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kühlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M.

Hum Gene Ther Clin Dev. 2013 Jun;24(2):86-98. doi: 10.1089/humc.2013.019.

6.

Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010).

Stocking C, Grez M, Fehse B, von Laer D, Itoh K, Prassolov V, Nowock J, Kühlcke K, Just U, Schröder T, Klump H, Schiedlmeier B, Grassman E, Meyer J, Li Z, Schambach A, Modlich U, Kustikova O, Galla M, Bode J, Zander A, Baum C.

Hum Gene Ther. 2010 Nov;21(11):1501-3. doi: 10.1089/hum.2010.1901. No abstract available.

PMID:
21091034
7.

Stem-cell gene therapy for the Wiskott-Aldrich syndrome.

Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C, Klein C.

N Engl J Med. 2010 Nov 11;363(20):1918-27. doi: 10.1056/NEJMoa1003548.

8.

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M.

Nat Med. 2010 Feb;16(2):198-204. doi: 10.1038/nm.2088. Epub 2010 Jan 24.

PMID:
20098431
9.

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M.

Nat Med. 2006 Apr;12(4):401-9. Epub 2006 Apr 2.

PMID:
16582916
10.

Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.

Schambach A, Schiedlmeier B, Kühlcke K, Verstegen M, Margison GP, Li Z, Kamino K, Bohne J, Alexandrov A, Hermann FG, von Laer D, Baum C.

Gene Ther. 2006 Jul;13(13):1037-47. Epub 2006 Mar 16.

PMID:
16541120
11.

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.

Fehse B, Ayuk FA, Kröger N, Fang L, Kühlcke K, Heinzelmann M, Zabelina T, Fauser AA, Zander AR.

Blood. 2004 Nov 15;104(10):3408-9. No abstract available.

PMID:
15525837
12.

Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population.

Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C, Fehse B.

Blood. 2003 Dec 1;102(12):3934-7. Epub 2003 Jul 24.

PMID:
12881303
13.

A novel 'sort-suicide' fusion gene vector for T cell manipulation.

Fehse B, Kustikova OS, Li Z, Wahlers A, Bohn W, Beyer WR, Chalmers D, Tiberghien P, Kühlcke K, Zander AR, Baum C.

Gene Ther. 2002 Dec;9(23):1633-8.

14.

Murine leukemia induced by retroviral gene marking.

Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kühlcke K, Eckert HG, Fehse B, Baum C.

Science. 2002 Apr 19;296(5567):497. No abstract available.

15.

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels.

Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuk F, Lehmann F, Stute N, Fauser AA, Zander AR, Eckert HG.

Mol Ther. 2002 Apr;5(4):473-8.

16.

Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice.

Carpinteiro A, Peinert S, Ostertag W, Zander AR, Hossfeld DK, Kühlcke K, Eckert HG, Baum C, Hegewisch-Becker S.

Int J Cancer. 2002 Apr 10;98(5):785-92.

17.

Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice.

Schiedlmeier B, Schilz AJ, Kühlcke K, Laufs S, Baum C, Zeller WJ, Eckert HG, Fruehauf S.

Hum Gene Ther. 2002 Jan 20;13(2):233-42.

PMID:
11812280
18.

Optimization of retroviral vector generation for clinical application.

Schilz AJ, Kühlcke K, Fauser AA, Eckert HG.

J Gene Med. 2001 Sep-Oct;3(5):427-36.

PMID:
11601756
19.

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.

Fehse B, Chukhlovin A, Kühlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein FG, Kröger N, Kabisch H, Hochhaus A, Zander AR.

J Hematother Stem Cell Res. 2001 Jun;10(3):419-25.

PMID:
11454317
20.

MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions.

Schilz AJ, Schiedlmeier B, Kühlcke K, Fruehauf S, Lindemann C, Zeller WJ, Grez M, Fauser AA, Baum C, Eckert HG.

Mol Ther. 2000 Dec;2(6):609-18.

21.

Human multidrug resistance-1 gene transfer to long-term repopulating human mobilized peripheral blood progenitor cells.

Schiedlmeier B, Wermann K, Kühlcke K, Eckert HG, Baum C, Fruehauf S, Zeller WJ.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S118-24.

PMID:
10933204
22.

Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1).

Eckert HG, Kühlcke K, Schilz AJ, Lindemann C, Basara N, Fauser AA, Baum C.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S114-7.

PMID:
10933203
23.

Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation.

Kühlcke K, Ayuk FA, Li Z, Lindemann C, Schilz A, Schade UM, Fauser AA, Zander AR, Eckert HG, Fehse B.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S96-8.

PMID:
10933199
25.

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements.

Ayuk F, Li Z, Kühlcke K, Lindemann C, Schade U, Eckert HG, Zander A, Fehse B.

Gene Ther. 1999 Oct;6(10):1788-92.

26.

Rapid and efficient cloning of proviral flanking fragments by kanamycin resistance gene complementation.

Fehse B, Kühlcke K, Langer A, Ostertag W, Lother H.

Nucleic Acids Res. 1999 Jan 15;27(2):706-7.

27.

Detection and spatial distribution of IL-2 receptors on mouse T-lymphocytes by immunogold-labeled ligands.

Breitfeld O, Kühlcke K, Lother H, Hohenberg H, Mannweiler K, Rutter G.

J Histochem Cytochem. 1996 Jun;44(6):605-13.

PMID:
8666745
28.

Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination.

Bergemann J, Kühlcke K, Fehse B, Ratz I, Ostertag W, Lother H.

Nucleic Acids Res. 1995 Nov 11;23(21):4451-6.

29.

Fibroblasts as efficient antigen-presenting cells in lymphoid organs.

Kündig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, et al.

Science. 1995 Jun 2;268(5215):1343-7.

PMID:
7761853
30.

Homodimeric murine interleukin-3 agonists indicate that ligand dimerization is important for high-affinity receptor complex formation.

Müther H, Kühlcke K, Gessner A, Abdallah S, Lother H.

Growth Factors. 1994;10(1):17-27.

PMID:
8179930
31.
32.

Antiviral immune responses of fully allogeneic irradiation bone marrow mouse chimeras.

Fang LB, Gessner A, Kühlcke K, Gossmann J, Lehmann-Grube F.

J Immunol. 1991 Nov 1;147(9):3133-8.

PMID:
1919008

Supplemental Content

Loading ...
Support Center